The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

The study, published in the Journal of Hepatology Reports, showed that low-medium fat dairy products may be protective, and ...

Discover a new study that has examined the influence of clinical and histologic risk factors on long-term MASLD outcomes in ...

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, into Phase III trials for treating MASH ...

MASLD diagnosis was associated with an increased risk for youth-onset type 2 diabetes among pediatric patients with obesity.

MASLD is related to nutrition, but evidence of an association between high-fat and low-fat dairy products is lacking. ‘Go ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

Excessive consumption of sugar can increase the risk of health problems. Here's what that looks like in the body.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Data on clinical outcomes in MASLD are lacking. This study’s goal was to provide a comprehensive meta-analysis of the ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...